Trial intelligence / Profile preview

Urinary coproporphyrin isomer ratio and delayed high-dose methotrexate elimination in lymphoid malignancies

2006-007035-27Phase 4Active

Sponsor: Assistance publique - Hôpitaux de Paris
Start: May 2007
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of methotrexate in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Individual methotrexate clearance. Started May 2007; status: active.

Drugs

methotrexate

Conditions

non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)

Beyond the preview

Go deeper on 2006-007035-27.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-007035-27.